Curavit Clinical Research is a Boston-based, all-virtual Contract Research Organization (CRO) that designs and runs decentralized clinical trials. Through its Virtual Clinical Site and STRATUS platform, Curavit recruits, enrolls, and monitors diverse patient populations remotely - eliminating physical site infrastructure and travel while improving data quality. The company specializes in trials for digital therapeutics (DTx) and partners with sponsors and existing CROs to fix the execution layer of clinical research, accelerating timelines and lowering costs.
Josh Rose is the CEO of Hawthorne Health, Inc. (formerly Hawthorne Effect), a Walnut Creek-based company building the largest community-based clinical trial site network in the U.S. A clinical research industry veteran with over 20 years of experience, Rose previously led decentralized clinical trial strategy at IQVIA and CVS Health before taking the helm at Hawthorne Health in early 2024. Under his leadership, Hawthorne has expanded to 75+ community locations, partnered with 40+ pharma sponsors, and pioneered a model that embeds certified clinical research staff inside independent pharmacies and patients' homes - bringing trials to communities that traditional research networks have long bypassed.
Dr. Michelle Longmire is the co-founder and CEO of Medable, the leading platform for agentic AI in clinical development. A Stanford-trained physician-scientist who grew up in a Los Alamos nuclear-research family, she pivoted from dermatology to founding Medable in 2015 after hitting enrollment walls in her own clinical research. Under her leadership, Medable has raised over $500 million in venture capital, deployed its platform in roughly 400 trials across 70 countries in 120 languages, and served more than one million patients globally - transforming how the world runs clinical trials.
Tom Lemberg is the Founder & CEO of Curebase, a San Francisco-based decentralized clinical trial platform that has enrolled over 60,000 patients across 60+ studies. A Harvard-trained computer scientist and molecular biologist, Lemberg built Curebase from his couch in 2017, joined Y Combinator in 2018, and raised $59M to transform how clinical trials work - letting patients participate from home and bringing their own doctors into the research process. Named to Forbes 30 Under 30 in 2022, he's on a mission to make clinical trials accessible to any patient, anywhere.